|
KMID : 1141520220370020183
|
|
Endocrinology and Metabolism
2022 Volume.37 No. 2 p.183 ~ p.194
|
|
|
Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature
|
|
Tay Wei Lin
Tay Donovan
|
|
|
Abstract
|
|
|
|
Denosumab, which has been approved for the treatment of osteoporosis since 2010, is a fully humanised monoclonal antibody against a cytokine, receptor activator of nuclear factor kappa B ligand (RANKL), involved in bone resorption. Continued use of denosumab results in a potent and sustained decrease in bone turnover, an increase in bone mineral density (BMD), and a reduction in vertebral and hip fractures. The anti-resorptive effects of denosumab are reversible upon cessation, and this reversal is accompanied by a transient marked increase in bone turnover that is associated with bone loss, and of concern, an increased risk of multiple vertebral fractures. In this review, we outline the effects of denosumab withdrawal on bone turnover markers, BMD, histomorphometry, and fracture risk. We provide an update on recent clinical trials that sought to answer how clinicians can transition away from denosumab safely with follow-on therapy to mitigate bone loss and summarise the recommendations of various international guidelines.
|
|
|
KEYWORD
|
|
|
Denosumab, RANK ligand, Bone density, Spinal fractures, Bone remodelling, Bone resorption, Osteoporosis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|
|